Amicus Therapeutics
Amicus Therapeutics63
About
What does Amicus Therapeutics do?
Amicus Therapeutics is a global biotechnology company focused on advancing therapies to treat rare diseases. As a wholly owned subsidiary of BioMarin Pharmaceutical Inc., it is guided by people living with rare diseases and aims to redefine expectations in this field. The company's website highlights its work in research and pipeline development, including clinical trials and expanded access programs for its medicines.
What is Amicus Therapeutics's revenue?
StartupHub estimates Amicus Therapeutics's annual revenue at $199.7M (range $105.7M to $356.5M, 64% confidence), based on comparable companies in the sector.
What is Amicus Therapeutics's valuation?
StartupHub estimates Amicus Therapeutics's effective valuation at $852.0M (range $500.0M to $1.2B, 10% confidence), based on comparable companies in the sector.
How much funding has Amicus Therapeutics raised?
Amicus Therapeutics has raised a total of $200M in funding. The most recent round on record is Series D.
Where is Amicus Therapeutics headquartered?
Amicus Therapeutics is headquartered in Philadelphia, United States.
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
What industry does Amicus Therapeutics operate in?
Amicus Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Rare Diseases.
How many employees does Amicus Therapeutics have?
Amicus Therapeutics has approximately 625 people on record.
No comments yet. Be the first to share your take.